ID: ALA69451

Max Phase: Preclinical

Molecular Formula: C26H28Cl2N4O

Molecular Weight: 483.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1

Standard InChI:  InChI=1S/C26H28Cl2N4O/c27-22-6-5-8-24(25(22)28)32-18-16-31(17-19-32)15-4-3-14-30-26(33)21-11-9-20(10-12-21)23-7-1-2-13-29-23/h1-2,5-13H,3-4,14-19H2,(H,30,33)

Standard InChI Key:  YJGPWNCHDJDGJR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 483.44

Molecular Weight (Monoisotopic): 482.1640

AlogP: 5.39

#Rotatable Bonds: 8

Polar Surface Area: 48.47

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 7.33

CX LogP: 5.41

CX LogD: 5.14

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.44

Np Likeness Score: -1.65

References

1. Newman AH, Cao J, Bennett CJ, Robarge MJ, Freeman RA, Luedtke RR..  (2003)  N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.,  13  (13): [PMID:12798330] [10.1016/s0960-894x(03)00389-5]

2. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH..  (2005)  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.,  48  (3): [PMID:15689168] [10.1021/jm049465g]

3. Newman AH, Grundt P, Nader MA..  (2005)  Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.,  48  (11): [PMID:15916415] [10.1021/jm040190e]

4. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH..  (2007)  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.,  50  (17): [PMID:17672446] [10.1021/jm0704200]

Source

Source(1):

• Scientific Literature